Virus Research,
Journal Year:
2024,
Volume and Issue:
351, P. 199507 - 199507
Published: Dec. 13, 2024
Chronic
hepatitis
B
(CHB)
is
a
significant
global
health
issue
affecting
approximately
254
million
individuals
worldwide.
Achieving
the
loss
of
surface
antigen
(HBsAg),
either
with
or
without
seroconversion
to
antibody
(HBsAb),
regarded
as
functional
cure
and
optimal
goal
for
addressing
CHB,
can
be
achieved
through
various
approaches,
including
induction
nucleos(t)ide
analogues
(NAs),
pegylated
interferon
alpha
(PegIFNα),
spontaneous
clearance
HBsAg.
Spontaneous
HBsAg
rare,
while
NAs
directly
inhibit
HBV
DNA,
they
are
unable
act
on
covalently
closed
circular
DNA
(cccDNA),
hence
inhibiting
production
clearing
extremely
challenging.
On
other
hand,
based
PegIFNα
shows
good
long-term
durability,
but
over
10
%
patients
still
experience
relapse,
mostly
within
48
weeks
after
cure.
Factors
related
CHB
antiviral
therapy
complex,
host
factors,
viral
environmental
etc.
The
integration
into
liver
cells,
persistence
cccDNA,
insufficient
cell
responses
compromised
T
function
pose
barriers
clearance.
Therefore,
this
study
systematically
reviewed
relevant
factors
potential
mechanisms
influencing
which
provide
basis
personalized
treatment,
help
predict
treatment
outcomes
assess
prognosis,
theoretical
support
advancement
novel
strategies
medications.
Gastroenterology report,
Journal Year:
2025,
Volume and Issue:
13
Published: Jan. 1, 2025
Steatotic
liver
disease
(SLD)
is
an
emerging
disease,
whereas
chronic
viral
hepatitis
the
renowned
cause
of
leading
to
cirrhosis
and
hepatocellular
carcinoma
(HCC).
The
impact
coexisting
SLD
in
B
(CHB)
on
liver-related
events
(LREs)
long
term
still
debated.
This
study
aims
compare
all-cause
mortality
LRE
between
CHB
patients
with
without
SLD.
retrospective
included
who
underwent
transient
elastography
2014
2021
at
a
tertiary-care
hospital.
Exclusion
criteria
were
those
controlled
attenuated
parameter
(CAP)
results,
interquartile
range/median
stiffness
measurement
(LSM)
>
30%,
follow-up
time
<
6
months,
virus
DNA
data
during
follow-up.
was
defined
as
CAP
≥
248
dB/m,
significant
fibrosis
(SF)
LSM
7
kPa,
≥11
kPa
or
imaging
evidence.
development
HCC
and/or
complications.
Among
532
(median
4.3
years),
present
161
(30.2%)
patients,
SF
found
186
(34.5%)
104
(19.6%)
had
baseline.
insignificantly
more
common
(40.1%
vs
32.4%,
P
=
0.068).
Long-term
outcomes
showed
SF,
not
SLD,
independently
associated
higher
adjusted
HR
13.85
(95%
confidence
interval
[CI]:
3.06-62.76,
0.001),
while
0.49
CI:
0.16-1.53,
0.22).
In
conclusion,
commonly
coexists
patients.
likely
have
baseline,
albeit
significantly.
complications
are
but
status.
Expert Review of Gastroenterology & Hepatology,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 5
Published: March 9, 2025
Introduction
Chronic
hepatitis
B
(CHB)
remains
a
major
global
health
challenge,
with
functional
cure
achieved
in
only
small
subset
of
patients.
Current
oral
antiviral
agents
effectively
suppress
viral
replication
but
fail
to
eliminate
the
virus
(HBV).
Recent
advances
immunomodulatory
therapies
offer
new
hope
for
improving
rates.
Clinical Liver Disease,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Jan. 1, 2024
Export
{"href":"Single
Video
Player","role":"media-player-id","content-type":"play-in-place","position":"float","orientation":"portrait","label":"","caption":"","object-id":[{"pub-id-type":"doi","id":""},{"pub-id-type":"other","content-type":"media-stream-id","id":"1_ymyuwtiv"},{"pub-id-type":"other","content-type":"media-source","id":"Kaltura"}]}
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(4), P. 390 - 390
Published: April 5, 2024
Background
and
Aims:
Chronic
hepatitis
B
virus
(HBV)
infection
is
a
global
public
health
challenge
since
more
than
250
million
individuals
are
affected
worldwide.
Since
different
treatment
modalities
available
not
all
patients
candidates
for
antiviral
treatment,
biomarkers
that
potentially
predict
the
possibility
of
HBsAg
clearance
seroconversion
may
be
useful
in
clinical
practice.
Patients
methods:
In
this
retrospective
study,
we
aimed
to
identify
factors
positively
correlated
with
large
cohort
371
chronic
treated
at
German
tertial
center
between
2005
2020.
Results:
Seroconversion
occurred
25/371
(6.7%)
loss
29/371
(7.8%)
HBV
infection.
Antiviral
therapy
was
associated
lower
chance
(seroconversion
14/260
(5.4%)
vs.
therapy-naïve
11/111
(9.9%),
p
=
0.027).
rates
were
higher
(very)
low
titers
DNA
(best
cut-off
value
357
IU/mL)
quantitative
HBsAg.
The
best
regard
IU/mL
(AUC
0.693
(95%-CI
0.063–0.422),
sensitivity
0.714,
specificity
0.729;
<
0.0005)
33,55
0.794
0.651–0.937),
0.949;
0.0005).
However,
male
gender
(seroconversion:
males
7.6%
females
2.7%,
0.036).
Conclusions:
Treatment-naïve
viral
load
inflammatory
activity
have
achieve
seroconversion.
absence
cirrhosis,
should
therefore
performed
patient
collective.
Hepatitis
B
surface
antigen
(HBsAg)
seroclearance
is
considered
the
functional
cure
and
optimal
treatment
endpoint
for
chronic
hepatitis
(CHB).
Patients
with
CHB
who
cleared
HBsAg
generally
have
a
favorable
clinical
course
minimal
risk
of
developing
hepatocellular
carcinoma
(HCC)
or
cirrhotic
complications.
Nevertheless,
minority
patients
still
develop
HCC
despite
seroclearance.
While
liver
cirrhosis
are
recommended
surveillance,
whether
other
non-cirrhotic
achieved
should
remain
on
surveillance
remains
unclear.
This
review
provides
an
overview
incidence
seroclearance,
factors
associated
occurrence
durability
after
development
role
scores,
implications
surveillance.
Existing
scores
reasonably
good
performance
in
In
era
artificial
intelligence,
future
prediction
models
based
intelligence
longitudinal
data
may
further
improve
accuracy
to
establish
foundation
score-based
strategy.
As
different
novel
virus
(HBV)
antiviral
agents
aiming
at
under
active
development,
new
knowledge
anticipated
natural
history
treated
HBV
drugs.
